Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicenter, randomized, parallel group open study to compare, in patients with postmenopausal osteoporosis, the effects of clodronate (Difosfonal) administered either intramuscularly at a dose of 100 mg 1 weekly, intramuscularly at a dose of 200 mg once every 2 weeks or orally at a dose of 800 mg daily (400 mg x 2), on BMD and markers of bone metabolism.

Next Previous
Search
Trial Profile

Multicenter, randomized, parallel group open study to compare, in patients with postmenopausal osteoporosis, the effects of clodronate (Difosfonal) administered either intramuscularly at a dose of 100 mg 1 weekly, intramuscularly at a dose of 200 mg once every 2 weeks or orally at a dose of 800 mg daily (400 mg x 2), on BMD and markers of bone metabolism.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 19 Dec 2022 Status changed from recruiting to discontinued.
  • 06 Jun 2012 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top